Synopsys (SNPS) Executive Chair Awarded Restricted Stock Units
SYNOPSYS INC
Subscribe to track SNPS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Synopsys (SNPS) Executive Chair Awarded Restricted Stock Units
Company: SYNOPSYS INC (SNPS) Form: 4 | Filed: 2025-12-18 Significance: Low
Insider: DE GEUS AART Title: EXECUTIVE CHAIR | Relationship: Director, Officer
Transaction: • Type: Grant • Shares: 2,693 Restricted Stock Units • Price: $0.00 • Value: $0 • Owned After: 2,693 (RSUs)
Key Insight: This is a routine equity grant to the Executive Chair as part of a standard compensation plan. The number of shares is negligible relative to the company's market capitalization.
Market Context: For a large-cap company like Synopsys ($72.41B market cap), such grants are common practice to align executive and shareholder interests and have minimal impact on the stock.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: SYNOPSYS INC (SNPS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Aart de Geus, the Executive Chair of Synopsys, received a routine grant of 2,693 Restricted Stock Units (RSUs) as part of his compensation package.
- Market Impact: The transaction is a non-market event with a negligible dilutive effect and is not expected to impact the stock price.
Company Information
| Field | Value |
|---|---|
| Company | SYNOPSYS INC |
| Ticker Symbol | SNPS |
| CIK | 0000883241 |
| Industry | SERVICES-PREPACKAGED SOFTWARE |
Insider Information
| Field | Value |
|---|---|
| Name | DE GEUS AART |
| CIK | 0001249802 |
| Title/Position | EXECUTIVE CHAIR |
| Relationship | Director, Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-12-16 |
| Transaction Code | A (Grant, award, or other acquisition) |
| Security Type | Restricted Stock Units |
| Shares Involved | 2,693 |
| Price Per Share | $0.00 |
| Total Value | $0.00 |
| Shares Owned After | 2,693 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0.00 |
| % of Market Cap | 0.0% |
| Shares Transacted | 2,693 |
| % of Shares Outstanding | 0.00145% |
| Post-Transaction Ownership | 2,693 RSUs (0.00145% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: Synopsys is a large-cap company with a market capitalization of $72.41 billion. This grant represents an insignificant fraction of the company's total value.
- Ownership Concentration: This grant establishes a small derivative holding for the insider. The total shares subject to the award are a very small percentage of the total shares outstanding.
- Dilution Impact: The potential dilution from these 2,693 shares is extremely low, at approximately 0.00145% of the 185.75 million shares outstanding. This will have no meaningful impact on existing shareholders.
- Transaction Significance: The transaction's value and share count are well below the thresholds for moderate or high significance. It is a routine compensatory grant.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: This is a non-market transaction and a standard form of executive compensation. It does not reflect any new insider sentiment based on market conditions.
Volume & Sentiment
- Expected Volume Impact: None. The grant does not involve open market trading.
- Sentiment Indicator: Neutral. The filing is informational and aligns with typical corporate governance practices.
Additional Context
Transaction Notes
- Vesting Schedule: The RSUs are subject to a vesting schedule. According to the filing's footnote, one-sixth of the units vest on June 15, 2026, followed by five equal semi-annual installments, contingent on continued service.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
